Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

29 Jun 2011

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis.

22 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.

7 Jun 2011

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

The first study of the social and ethical issues associated with a provocative approach to treatment for ulcerative colitis has found that the majority of potential patients are eager for what is now called "fecal microbiota transplantation" to become available, although many have concerns about donor selection, screening, and methods of delivery.

3 Jun 2011

Shield raises EUR8.2M through Series A financing

Shield Therapeutics, the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has successfully raised EUR8.2m from Inventages Venture Capital (Inventages) in its first institutional financing round.

1 Jun 2011

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

A protein isolated from beneficial bacteria found in yogurt and dairy products could offer a new, oral therapeutic option for inflammatory bowel disorders, suggests a study led by Vanderbilt University Medical Center researcher Fang Yan, M.D., Ph.D.

24 May 2011

New RHUCIN study data in acute HAE attacks presented at 7th C1 Inhibitor Deficiency Workshop

Santarus, Inc., a specialty biopharmaceutical company, today announced that new data from open-label studies evaluating the efficacy and safety of the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema were presented at the 7th C1 Inhibitor Deficiency Workshop on May 20 - 22, 2011 in Budapest, Hungary.

23 May 2011

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

Naltrexone reduced inflammation in Crohn's patients in a research study at Penn State College of Medicine.

20 May 2011

AGA honors four young gastroenterologists with prestigious Research Scholar Awards

The American Gastroenterological Association Research Foundation has announced its 2011 research scholars. The grants have been awarded to four outstanding young gastroenterologists who promise to make significant strides in the field of gastrointestinal research.

6 May 2011

Santarus' budesonide MMX Phase III data in ulcerative colitis to be presented at DDW 2011

Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.

3 May 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.

30 Apr 2011

White youths less likely to be tested for STI in pediatric emergency department

When adolescent females visit a pediatric emergency department with complaints that may signal a sexually transmitted infection, white youths are less likely to be tested than blacks, according to a study to be presented Saturday, April 30, at the Pediatric Academic Societies annual meeting in Denver.

30 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Pfizer Inc. announced today top-line results from the ORAL Standard and ORAL Step Phase 3 studies of tofacitinib, an investigational, novel, oral JAK inhibitor.

29 Apr 2011

IBD patients at greater risk of death if infected with Clostridium difficile

Patients admitted to hospital with inflammatory bowel disease (IBD) face a sixfold greater risk of death if they become infected with Clostridium difficile, a new study has found. The researchers say IBD patients should be screened on admission to protect them from serious illness.

20 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

AHRQ finds 52% increase in medication side effects, injuries between 2004 and 2008

The number of people treated in U.S. hospitals for illnesses and injuries from taking medicines jumped 52 percent between 2004 and 2008 - from 1.2 million to 1.9 million - according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

15 Apr 2011

Experts to discuss latest findings in IBD research at Rome meeting

Experts from 11 countries will gather this week in Rome to discuss innovative strategies for studying and treating Inflammatory Bowel Diseases.

12 Apr 2011

AJG publishes new review on Inflammatory Bowel Disease management

The American College of Gastroenterology published a new evidence-based systematic review on the management of Inflammatory Bowel Disease as a supplement to The American Journal of Gastroenterology for April 2011, a special issue entirely dedicated to IBD.

8 Apr 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

Shield raises EUR8.2M through Series A financing

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

New RHUCIN study data in acute HAE attacks presented at 7th C1 Inhibitor Deficiency Workshop

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

AGA honors four young gastroenterologists with prestigious Research Scholar Awards

Santarus' budesonide MMX Phase III data in ulcerative colitis to be presented at DDW 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

White youths less likely to be tested for STI in pediatric emergency department

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

IBD patients at greater risk of death if infected with Clostridium difficile

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

AHRQ finds 52% increase in medication side effects, injuries between 2004 and 2008

Experts to discuss latest findings in IBD research at Rome meeting

AJG publishes new review on Inflammatory Bowel Disease management

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in